Jounce rings out the old year with a $75M IPO bid for the New Year

Five months af­ter Cel­gene part­nered with Jounce Ther­a­peu­tics on a $2.56 bil­lion de­vel­op­ment deal, the Cam­bridge, MA-based biotech is end­ing the year with a $75 mil­lion IPO bid.

Now at the Phase I/II stage of de­vel­op­ment, Jounce was launched by Third Rock and gained at­ten­tion for an im­muno-on­col­o­gy strat­e­gy that in­volved in amp­ing up an im­mune sys­tem at­tack on can­cer. Cel­gene bought in to the com­pa­ny with $261 mil­lion for eq­ui­ty and an up­front in Ju­ly. The first batch of safe­ty and ef­fi­ca­cy da­ta are ex­pect­ed next year. And there’s al­so a PD-1 check­point pro­gram in the works for fu­ture com­bo pro­grams.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER